glp-1 obesity drugs news today drug 2025 A nice article in The Hindu today highlights the How Supply and Demand for
Description
Retatrutide vs Semaglutide: Evidence-based comparison of the investigational triple GIP/GLP-1/glucagon agonist versus the FDA-approved GLP-1 agonist
Learn how GLP-1 medications may affect vision, from blurry sight to rare risks, plus potential eye health benefits and when to see an eye doctor.
The GLP-1 market is expected to hit $200 billion by 2031, according to a new study.
78.64.4 l/min/gkw, sodium excretion 7.40.8 vs
Its predominant action is on the postprandial glucose levels, with extraglycemic effects on fat metabolism and endovascular function
The advent of incretin mimetics such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has enriched the armamentarium for diabetes management owing to their glycaemic as well as extra-glycaemic benefits
